Introduction
Sodium valproate (sodium dipropylacetate, Epilim, Depakine) has been used as an antiepileptic drug in several European countries for several years and there have been many reports of its efficacy in most types of epilepsy.1-3 All but one4 of these reports, however, describe trials in which no attempt was made to control for observer bias by comparing the new drug with a placebo or an established antiepileptic drug. We thought that it was necessary to compare sodium valproate with a placebo to establish beyond doubt its antiepileptic effect. Because it is difficult to justify treating epileptic patients with a placebo alone, we chose to add either the active drug or a placebo on a doubleblind crossover basis to the existing medication of patients with uncontrolled epilepsy.
Patients and methods
Twenty long-stay patients at the National Hospitals Special Centre for Epilepsy were studied ( We assessed the response to the drug by recording the major and minor fits that occurred each week of the trial. Although the staff in charge of the residential houses and work centres were trained in observing and recording fits, some fits, particularly minor ones, went unrecorded. This deficiency, however, should have occurred equally in the placebo and active drug treatment periods. Fits were assessed as two types: tonic-clonic seizures ("major" attacks); and all other types, including absence attacks, adversive attacks, and focal and psychomotor fits ("minor" attacks). To examine the possibility of drug interaction serum phenytoin and phenobarbitone levels were measured by enzyme immunoassay in seven patients before administration of sodium valproate and at the end of the assessment period in which the active drug had been used. Furthermore, tracer doses of "4C-labelled phenytoin were given by mouth before and during sodium valproate treatment to measure the serum half life of the carbon label. 5
Results
Control of fits-The effect of sodium valproate compared with placebo is shown in tables III and IV. These results were significantly in favour of sodium valproate (for major fits, P <005; for minor fits, P <0 01, using Wilcoxon signed-ranks test). The significance of the differences was confirmed by an analysis of variance. The frequency of major fits during valproate treatment was reduced to an average of 3500 of the frequency on placebo. The corresponding reduction in minor fits was to 57% of the frequency on placebo.
Adverse effects-Thirteen patients showed signs of toxicity, comprising drowsiness, ataxia, and nausea (table III) . These signs were usually mild and transient, however, and did not necessitate withdrawal of the test drug in any patient. In only three patients was it necessary to reduce the dose of primidone or phenobarbitone because of drowsiness, but in one of these it was discovered on breaking the code that the patient was receiving placebo at the time of drug reduction.
Interaction with phenobarbitone and phenytoin-Serum phenobarbitone levels measured in duplicate or triplicate showed a consistent rise in each of seven patients in whom the estimations were performed. The dose of sodium valproate used in this trial was not large; the plasma levels of valproate found in four patients in whom they were measured ranged from 237-475 ,zmol/l (34-68 ,sg/ml) and were within the range expected from a dose of 1200 mg/day.
A "therapeutic range" of 350-700,emol/I (50-100 tlg/ml) has been cited by Schobben et al1, though no prospective studies have been performed to establish such a range.
The patients selected for this trial had severe epilepsy that had responded inadequately to various combinations of established drugs. The useful therapeutic effect that was produced by sodium valproate in these patients is therefore promising. Further controlled trials are necessary, however; firstly, to establish the part played by concurrent phenobarbitone or primidone treatment in the therapeutic response to valproate; and, secondly, to compare its efficacy with other established drugs used for the various types of epilepsy.
